(Q38078178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Monoclonal antibodies for prophylactic and therapeutic use against viral infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Edward Wright

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Craig J van Dolleweerd

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Julian Ma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

6

Anthony R Fooks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Leonard Both

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

29 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

1553-1559

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23370150%20AND%20SRC:MED&resulttype=core&format=json

Passive immunity in the prevention of rabies.

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Passive antibody therapy for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

The growth and potential of human antiviral monoclonal antibody therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Motavizumab for the prevention of respiratory syncytial virus infection in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Monoclonal antibody-based therapies for microbial diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Therapeutic antibodies for autoimmunity and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Potent antibody therapeutics by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

FcRn: the neonatal Fc receptor comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Antibody epitope exposure and neutralization of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

CCR5 monoclonal antibodies for HIV-1 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Antibodies against viruses: passive and active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Occupancy and mechanism in antibody-mediated neutralization of animal viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Fc receptor-mediated antiviral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Humoral immunity to HIV-1: neutralisation and antibody effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Fc receptor but not complement binding is important in antibody protection against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

The challenge to provide affordable rabies post-exposure treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

7 January 2021

Bats and lyssaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

The immune response to rabies virus infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Generation and assembly of secretory antibodies in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Few and far between: how HIV may be evading antibody avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Distribution and three-dimensional structure of AIDS virus envelope spikes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Dimeric 2G12 as a potent protection against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Enhanced HIV-1 neutralization by antibody heteroligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Design, expression, and characterization of a multivalent, combination HIV microbicide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A review of palivizumab and emerging therapies for respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Strategies and challenges for the next generation of therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Cross-reacting antibodies enhance dengue virus infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Antibodies to West Nile virus: a double-edged sword

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Antibody recognition of a highly conserved influenza virus epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A highly conserved neutralizing epitope on group 2 influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

West Nile virus–induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Drug and gene targeting to the brain with molecular Trojan horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

A cost-effective approach to administering palivizumab in a centralised nurse-led community clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

HIV drugs made in tobacco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

7 January 2021

inferred from DOI database lookup

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

7 January 2021

inferred from DOI database lookup

Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.025

7 January 2021

inferred from DOI database lookup

Continuous cultures of fused cells secreting antibody of predefined specificity. 1975

1 reference

12 December 2020

An Immunising Serum against Rinderpest

1 reference

12 December 2020

Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab

1 reference

12 December 2020

[The mechanism of diphtheria immunity and tetanus immunity in animals. 1890].

1 reference

12 December 2020

Overview of antibody phage-display technology and its applications

1 reference

12 December 2020

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies

1 reference

12 December 2020

Efficient production of anti-(hepatitis B virus) antibodies and their neutralizing activity in chimpanzees

1 reference

12 December 2020

Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus

1 reference

12 December 2020